CFBI Archives - Page 2 of 2

Developments

Can-Fite expands development of CF102 into NASH

Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) drug candidate, CF102, which is currently in Phase 2 trials for hepatocellular carcinoma (HCC), the most common form of liver cancer, will be expanded into the treatment...

November 23, 2015

Developments

MOA of Can-Fite’s CF602 can improve sexual dysfunction

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has reported new findings for its CF602 drug candidate showing a defined mechanism of action in erectile dysfunction similar to sildenafil (Viagra) in a rat model of...

October 22, 2015

Developments

Can-Fite BioPharma in registered direct offering

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has entered into definitive agreements with existing institutional investors to receive gross proceeds of about $4.8-million. The company will issue 1,109,196 registered...

October 13, 2015

Developments

EMA grants orphan designation to Can-Fite’s CF102

Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) oncology drug candidate, CF102, has been granted orphan drug designation by the European Medicines Agency (EMA) for the indication of hepatocellular carcinoma (HCC), the...

October 12, 2015

Markets

Can-Fite in $9-million registered direct offering

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has entered into definitive agreements with institutional investors to raise $9-million through the sale of 2,068,966 American Depository Shares (ADS) at a price of $4.35...

September 21, 2015

Developments

Can-Fite gets FDA fast track for liver cancer drug

The FDA has granted Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) drug candidate, CF102, fast track designation asv a second line treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer...

September 17, 2015

Feature

Can-Fite preparing protocol for advanced psoriasis trial

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) is preparing the protocol for its next advanced psoriasis trial with its CF101 oral drug candidate, even though an earlier Phase 2/3 study did not meet its primary endpoint...

September 8, 2015

Tag - CFBI

Can-Fite expands development of CF102 into NASH

MOA of Can-Fite’s CF602 can improve sexual dysfunction

Can-Fite BioPharma in registered direct offering

EMA grants orphan designation to Can-Fite’s CF102

Can-Fite in $9-million registered direct offering

Can-Fite gets FDA fast track for liver cancer drug

Can-Fite preparing protocol for advanced psoriasis trial

General

More